COVI-GUARD

COVID-19 Treatment: COVI-GUARD (Neutralizing Antibody – STI 1499)

Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVI-GUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2 infection.